134 related articles for article (PubMed ID: 1974853)
1. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.
Schmidt CJ; Taylor VL
Eur J Pharmacol; 1990 May; 181(1-2):133-6. PubMed ID: 1974853
[TBL] [Abstract][Full Text] [Related]
2. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.
Hekmatpanah CR; Peroutka SJ
Eur J Pharmacol; 1990 Feb; 177(1-2):95-8. PubMed ID: 1971219
[TBL] [Abstract][Full Text] [Related]
3. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine.
Schmidt CJ; Taylor VL
Biochem Pharmacol; 1987 Dec; 36(23):4095-102. PubMed ID: 2891359
[TBL] [Abstract][Full Text] [Related]
4. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons.
Schmidt CJ; Taylor VL
Eur J Pharmacol; 1988 Oct; 156(1):121-31. PubMed ID: 2463176
[TBL] [Abstract][Full Text] [Related]
5. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog.
Johnson M; Hanson GR; Gibb JW
Eur J Pharmacol; 1989 Jun; 165(2-3):315-8. PubMed ID: 2570704
[TBL] [Abstract][Full Text] [Related]
6. Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system.
Johnson M; Hanson GR; Gibb JW
Biochem Pharmacol; 1989 Dec; 38(23):4333-8. PubMed ID: 2480796
[TBL] [Abstract][Full Text] [Related]
7. Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus.
García-Osta A; Del Río J; Frechilla D
Brain Res Mol Brain Res; 2004 Jul; 126(2):181-7. PubMed ID: 15249142
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity.
Johnson M; Stone DM; Bush LG; Hanson GR; Gibb JW
Eur J Pharmacol; 1989 Feb; 161(2-3):181-8. PubMed ID: 2470597
[TBL] [Abstract][Full Text] [Related]
9. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
[TBL] [Abstract][Full Text] [Related]
10. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine.
Johnson M; Mitros K; Stone DM; Zobrist R; Hanson GR; Gibb JW
J Pharmacol Exp Ther; 1992 May; 261(2):586-91. PubMed ID: 1374469
[TBL] [Abstract][Full Text] [Related]
11. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.
Schmidt CJ; Abbate GM; Black CK; Taylor VL
J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728
[TBL] [Abstract][Full Text] [Related]
12. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system.
Pan HS; Wang RY
Brain Res; 1991 Jan; 539(2):332-6. PubMed ID: 1675911
[TBL] [Abstract][Full Text] [Related]
13. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats.
Callaway CW; Wing LL; Geyer MA
J Pharmacol Exp Ther; 1990 Aug; 254(2):456-64. PubMed ID: 1974635
[TBL] [Abstract][Full Text] [Related]
14. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.
Stone DM; Johnson M; Hanson GR; Gibb JW
J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215
[TBL] [Abstract][Full Text] [Related]
15. Reduction of [3H]6-nitroquipazine-labelled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine.
Hashimoto K; Goromaru T
Fundam Clin Pharmacol; 1990; 4(6):635-41. PubMed ID: 1710592
[TBL] [Abstract][Full Text] [Related]
16. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.
Stone DM; Stahl DC; Hanson GR; Gibb JW
Eur J Pharmacol; 1986 Aug; 128(1-2):41-8. PubMed ID: 2875893
[TBL] [Abstract][Full Text] [Related]
17. Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine.
Elayan I; Gibb JW; Hanson GR; Foltz RL; Lim HK; Johnson M
Eur J Pharmacol; 1992 Oct; 221(2-3):281-8. PubMed ID: 1358654
[TBL] [Abstract][Full Text] [Related]
18. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons.
Battaglia G; Yeh SY; De Souza EB
Pharmacol Biochem Behav; 1988 Feb; 29(2):269-74. PubMed ID: 2452449
[TBL] [Abstract][Full Text] [Related]
19. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
Colado MI; Murray TK; Green AR
Br J Pharmacol; 1993 Mar; 108(3):583-9. PubMed ID: 7682129
[TBL] [Abstract][Full Text] [Related]
20. In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine.
Stone DM; Hanson GR; Gibb JW
J Neurochem; 1989 Aug; 53(2):572-81. PubMed ID: 2568404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
